Israel - English - Ministry of Health

novartis israel ltd - secukinumab - solution for injection - secukinumab 150 mg/ml - secukinumab - - plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. - paediatric plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. - psoriatic arthritis: cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate. - axial spondyloarthritis (axspa) : •ankylosing spondylitis (as, radiographic axial spondyloarthritis) cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. •non-radiographic axial spondyloarthritis (nr-axspa) cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (nsaids). - juvenile idiopathic arthritis (jia) •enthesitis-related arthritis (era) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitisrelated arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. •juvenile psoriatic arthritis (jpsa) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy

European Union - English - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunosuppressants - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy.psoriatic arthritiscosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate.axial spondyloarthritis (axspa)ankylosing spondylitis (as, radiographic axial spondyloarthritis)cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids).juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Canada - English - Health Canada

novartis pharmaceuticals canada inc - secukinumab - powder for solution - 150mg - secukinumab 150mg - misc. skin and mucous membrane agents

Canada - English - Health Canada

novartis pharmaceuticals canada inc - secukinumab - solution - 150mg - secukinumab 150mg - misc. skin and mucous membrane agents

Israel - English - Ministry of Health

novartis israel ltd - secukinumab - powder for solution for injection - secukinumab 150 mg/dose - secukinumab - - plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.- paediatric plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.- psoriatic arthritis: cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate.- axial spondyloarthritis (axspa) :• ankylosing spondylitis (as, radiographic axial spondyloarthritis) cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.• non-radiographic axial spondyloarthritis (nr-axspa) cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (nsaids).- juvenile idiopathic arthritis (jia)• enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. • juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - secukinumab - injection, powder, for solution - secukinumab 150 mg/vial

Canada - English - Health Canada

novartis pharmaceuticals canada inc - secukinumab - solution - 75mg - secukinumab 75mg

Canada - English - Health Canada

novartis pharmaceuticals canada inc - secukinumab - solution - 300mg - secukinumab 300mg

Canada - English - Health Canada

novartis pharmaceuticals canada inc - secukinumab - solution - 300mg - secukinumab 300mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

novartis pharma ag, switzerland - secukinumab - solution for injection - 150 mg/ml